---
id: helicobacter-pylori-treatment_058
category: organisms
tags: [helicobacter-pylori, H-pylori, bismuth-quadruple-therapy, clarithromycin-resistance, PPI]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Helicobacter pylori: Treatment

**Q:** What are the current treatment recommendations for Helicobacter pylori infection according to 2024 ACG guidelines?

**A:**

**Treatment Goals:**
- Eradicate H. pylori (cure rate >90%)
- Heal peptic ulcers
- Prevent complications (gastric cancer, bleeding, perforation)

---

**2024 ACG Guidelines: MAJOR PARADIGM SHIFT**

**Old Approach (2017):** PPI + clarithromycin + amoxicillin (triple therapy) was first-line

**New Approach (2024):**
- **Bismuth quadruple therapy (BQT)** is now PREFERRED for treatment-naïve patients
- **Do NOT use clarithromycin triple therapy** unless antibiotic susceptibility proven

**Reason:** Rising clarithromycin resistance (>15% in US, >20% globally)

---

**First-Line Treatment: Bismuth Quadruple Therapy (BQT)**

**Regimen Components:**

| **Drug** | **Dosing** | **Duration** |
|----------|------------|--------------|
| **PPI** (standard dose) | BID | 14 days |
| **Bismuth subsalicylate** | 524 mg (2 tabs) QID | 14 days |
| **Tetracycline** | 500 mg QID | 14 days |
| **Metronidazole** | 500 mg TID-QID | 14 days |

**Pre-Packaged Option:**
- **Pylera** (bismuth subcitrate + metronidazole + tetracycline in single capsule)
  - 3 capsules QID x 10 days + PPI BID x 10 days

**Efficacy:**
- **Eradication rate: 85-95%**
- Overcomes clarithromycin resistance
- NOT affected by metronidazole resistance

**Advantages:**
- Effective regardless of clarithromycin resistance
- No antibiotic susceptibility testing needed

**Disadvantages:**
- Pill burden (12+ pills/day)
- Side effects: Nausea, dark stools (bismuth), metallic taste
- Tetracycline contraindicated in pregnancy, children <8 years

---

**Alternative First-Line Regimens:**

**1. Rifabutin Triple Therapy:**

| **Drug** | **Dosing** | **Duration** |
|----------|------------|--------------|
| **PPI** (standard dose) | BID | 14 days |
| **Amoxicillin** | 1g TID | 14 days |
| **Rifabutin** | 150 mg BID | 14 days |

**Efficacy:** 85-95%

**Use:** Alternative to BQT (especially if tetracycline contraindicated)

**Caution:** Rifabutin interactions, cost

**2. Vonoprazan-Amoxicillin Dual Therapy:**

| **Drug** | **Dosing** | **Duration** |
|----------|------------|--------------|
| **Vonoprazan** (P-CAB) | 20 mg BID | 14 days |
| **Amoxicillin** | 1g TID | 14 days |

**Efficacy:** 85-90%

**Note:** Vonoprazan is a **potassium-competitive acid blocker (P-CAB)** - more potent acid suppression than PPI

**Availability:** FDA-approved 2022 (limited availability, expensive)

---

**When to Consider Clarithromycin Triple Therapy:**

**2024 ACG: NOT RECOMMENDED unless:**
- Clarithromycin susceptibility **proven** by culture or molecular testing

**Regimen (If Susceptible):**

| **Drug** | **Dosing** | **Duration** |
|----------|------------|--------------|
| **PPI** (standard dose) | BID | 14 days |
| **Clarithromycin** | 500 mg BID | 14 days |
| **Amoxicillin** | 1g BID | 14 days |

**Problem:**
- Clarithromycin resistance >15% in US → eradication rate <80% if resistant
- **Should NOT be used empirically**

---

**Second-Line Treatment (If First-Line Fails):**

**Options:**

**1. Bismuth Quadruple Therapy** (if first-line was clarithromycin-based)

**2. Levofloxacin Triple Therapy:**

| **Drug** | **Dosing** | **Duration** |
|----------|------------|--------------|
| **PPI** (standard dose) | BID | 14 days |
| **Levofloxacin** | 500 mg daily | 14 days |
| **Amoxicillin** | 1g BID | 14 days |

**Efficacy:** 75-85%

**Problem:** Rising levofloxacin resistance

**3. Culture + Antibiotic Susceptibility Testing:**
- Recommended after **2 treatment failures**
- Tailor therapy based on susceptibility

---

**Special Populations:**

**Penicillin Allergy:**
- Bismuth quadruple therapy (replace amoxicillin with metronidazole if needed)
- Rifabutin triple therapy

**Pregnancy:**
- **Defer treatment until after delivery** (most regimens contraindicated)
- If urgent: Amoxicillin + PPI (monotherapy, low efficacy)

**Children:**
- Bismuth quadruple therapy (if >8 years, tetracycline OK)
- If <8 years: Amoxicillin + clarithromycin + PPI (if susceptible)

---

**PPI Dosing:**

**Standard Doses (BID):**
- Omeprazole 20 mg BID
- Lansoprazole 30 mg BID
- Esomeprazole 40 mg BID
- Pantoprazole 40 mg BID
- Rabeprazole 20 mg BID

**High-Dose PPI:**
- May improve efficacy in some regimens (e.g., omeprazole 40 mg BID)

---

**Test-of-Cure (MANDATORY):**

**All patients should have test-of-cure:**
- **≥4 weeks after completing treatment**
- Stop PPI x 2 weeks before testing
- Use **urea breath test (UBT)** or **stool antigen test (SAT)**
- NOT serology (antibodies persist)

---

**Comparison Table: 2024 Treatment Options**

| **Regimen** | **Eradication Rate** | **Pill Burden** | **Resistance Profile** | **Cost** |
|-------------|---------------------|-----------------|------------------------|----------|
| **Bismuth quadruple** | 85-95% | High (12+/day) | Overcomes clarithromycin resistance | Low |
| **Rifabutin triple** | 85-95% | Moderate | Effective | High |
| **Vonoprazan-amoxicillin** | 85-90% | Low | Effective | High |
| **Clarithromycin triple** | <80% (if resistant) | Low | Fails if clarithromycin resistant | Low |
| **Levofloxacin triple** | 75-85% | Low | ↑ Levofloxacin resistance | Moderate |

---

**Mnemonic: "BQT = Bismuth Quadruple Therapy Tops Clarithromycin"**
- **B**ismuth subsalicylate
- **Q**ID dosing (4 times daily)
- **T**etracycline + metronidazole + PPI

**Mnemonic: "2024 H. pylori = Bye-Bye Clarithromycin"**
- **B**ismuth quadruple therapy NOW first-line
- **B**ye-bye to clarithromycin triple therapy (unless susceptibility proven)
- **C**larithromycin resistance >15% → NOT empiric

**Mnemonic: "BISMUTH" for BQT components**
- **B**ismuth subsalicylate
- **I**nhibit acid (PPI)
- **S**ix components total (no, just 4!)
- **M**etronidazole
- **U**sed for 14 days
- **T**etracycline
- **H**elps overcome clarithromycin resistance

---

**Clinical Pearls:**
- **2024 paradigm shift:** Bismuth quadruple therapy (BQT) is now PREFERRED first-line
- **Do NOT use clarithromycin triple therapy empirically** (>15% resistance in US)
- BQT effective regardless of clarithromycin/metronidazole resistance
- **Test-of-cure MANDATORY** for all patients (≥4 weeks post-treatment)
- **Culture + susceptibility after 2 treatment failures**
- Pylera (pre-packaged BQT) improves adherence but more expensive
- Vonoprazan (P-CAB) emerging as alternative to PPI (more potent acid suppression)
- **Rifabutin triple therapy = excellent alternative** to BQT (85-95% efficacy)
- Rising levofloxacin resistance → avoid as first-line
- **2017 → 2024 change reflects global antibiotic resistance crisis**

**Media:** None

**Sources:** [ACG 2024 - H. pylori treatment guideline update], [UIC Drug Info 2025 - Latest H. pylori guidelines], [PMC 2024 - Bismuth quadruple vs clarithromycin-resistant], [MDPI 2025 - Modified bismuth quadruple therapy meta-analysis], [Gut and Liver 2024 - 7-day vs 14-day BQT], [MDPI 2024 - Metronidazole triple after clarithromycin failure], [Medscape 2024 - H. pylori treatment]
